Company
OBP in Oman
We are a visionary presence in the biopharmaceutical landscape, driven to transform healthcare. Through innovation, global collaborations, and accessible treatments, we’re dedicated to nurturing a healthier future for all.
about company
Manufacturing Technologies
Technology
Operate a cutting-edge, continuous single-use production line utilizing both CHO and baculovirus platforms to seamlessly and consistently manufacture high-quality biopharmaceutical products.
R&D
Product
High-Tech Solutions
Utilize advanced technology to provide accessible healthcare by producing biosimilar products for everyone.
Products
Uniting Arabs
in a Borderless
World
We seek to create achievements for the health of the
global community to make Arabs proud.
Areas of focus
Advancing biosimilar mAbs and gene-modified cell therapies with cost-effective, high-tech solutions for global healthcare, ensuring accessibility and reliability.
Monoclonal Antibodies & Biologics
Includes biosimilar mAbs, ADCs, and fusion proteins for immunology and oncology.
Gene therapy
Covers in vivo gene therapies using AAV, lentivirus, CRISPR, or mRNA-based approaches.
2030 Vision
20M
Empowering Lives:
Touching 20 Million Lives
250,000 Patients
Healing autoimmunity Together
Empowering life of 250,000 Patients
10M
Health Equity:
Safeguarding 10 Million Lives
+1000 Lives
Leading Gene Therapy
Transforming +1000 Lives
15K Stories
Shaping Cancer Stories
Creating 150,000 Stories of Hope
+$200M
Innovation for Impact
Investing +$200 Million for Progress
Adalix
- INN: Adalimumab
- Indications: Treatment of autoimmune diseases such as rheumatoid arthritis, psoriatic arthritis, Crohn’s disease, and ulcerative colitis.
- Strengths: 40mg/0.4ml in Pre-filled Syringe (PFS)
- Mechanism of Action: TNF-α inhibitor that reduces inflammation by blocking tumor necrosis factor-alpha (TNF-α).
Opal Bio Pharma is the vanguard of a new era in Arab healthcare, pioneering breakthroughs that will redefine medicine and empower Oman and the entire GCC to lead in global health innovation.
Saad Al Junaibi
Founder and Chairman
Oncology in The Middle East and North Africa (MENA)
The realm of oncology in The Middle East and North Africa (MENA) is a narrative of constant evolution, striving to meet the growing demands of cancer care. As cancer cases continue to rise in the region, the need for advanced oncology care has never been more pressing.
Dream Team
At Opal Bio Pharma, we bring global experts and healthcare professionals together with a unified mission: to advance the medical landscape and provide vital healthcare solutions. If you’re driven to make a significant impact in this industry, we invite you to submit your resume.
